Literature DB >> 21466776

[Level of evidence for therapeutic drug monitoring of aminoglycosides].

Nicolas Venisse1, Audrey Boulamery.   

Abstract

Aminoglycosides are major antibiotics indicated for the treatment of infection with gram-negative bacilli. They are characterized by high clinical effectiveness but their main drawback is the occurrence of toxicity in a significant number of patients. Pharmacokinetic parameters of aminoglycosides exhibit wide inter-individual variability and the relationships between concentration and effect have been clearly demonstrated. Consistent studies have demonstrated that therapeutic drug monitoring (TDM) of aminoglycosides administered in multiple daily doses was cost-effective in maximising antibiotic efficacy and/or reducing incidence of toxicity. Therefore TDM of aminoglycosides should be considered "essential". Level of evidence for TDM of aminoglycosides administered once daily is not so clearly demonstrated however it should be highly recommended.
© 2011 Société Française de Pharmacologie et de Thérapeutique.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21466776     DOI: 10.2515/therapie/2011001

Source DB:  PubMed          Journal:  Therapie        ISSN: 0040-5957            Impact factor:   2.070


  2 in total

1.  An international survey on aminoglycoside practices in critically ill patients: the AMINO III study.

Authors:  Claire Roger; Benjamin Louart; Loubna Elotmani; Greg Barton; Leslie Escobar; Despoina Koulenti; Jeffrey Lipman; Marc Leone; Laurent Muller; Caroline Boutin; Julien Amour; Iouri Banakh; Joel Cousson; Jeremy Bourenne; Jean-Michel Constantin; Jacques Albanese; Jason A Roberts; Jean-Yves Lefrant
Journal:  Ann Intensive Care       Date:  2021-03-19       Impact factor: 6.925

2.  Evaluation of the clinical practice of aminoglycoside use in paediatric patients in Kenya: findings and implications for lower-middle income countries.

Authors:  Elias Joseph Onyango; Faith Okalebo; Margaret Oluka; Rosaline Kinuthia; Loice Achieng; Brian Godman; Amanj Kurdi
Journal:  JAC Antimicrob Resist       Date:  2020-01-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.